BPC-157 for Tendon and Ligament Injuries: What the Studies Show

BPC-157 has improved tendon, ligament, and muscle healing in rats across roughly two decades of laboratory studies, but no controlled human trial has ever tested it for a tendon or ligament injury. A 2025 systematic review of the orthopedic literature found 35 preclinical studies and a single human study: a retrospective phone survey of 12 people who received knee injections, with no control group. As of September 2026, BPC-157 is not FDA approved for any use and is prohibited in sport. The treatment with the strongest human evidence for tendon problems is still progressive loading exercise.

How tendons and ligaments heal, and why it takes so long

Tendons connect muscle to bone. Ligaments connect bone to bone. Both are dense ropes of tightly aligned collagen, and both are built for strength, not for fast repair. To judge any claim that a compound speeds their healing, it helps to know what normal healing looks like and where it falls short.

Built for load, not for repair

Healthy tendon is made mostly of type I collagen, the strong, rope-like form, with smaller amounts of type III collagen. Compared with most tissues it has few cells and few blood vessels. The main resident cells, called tenocytes, sit scattered among the collagen fibers and maintain them slowly. Fewer cells and less blood flow mean fewer workers and fewer supply lines when something tears.

A striking Danish study shows how little adult tendon renews itself. Researchers measured carbon-14 left in the atmosphere by nuclear bomb tests of 1955 to 1963 in 28 forensic samples of human Achilles tendon. The tendon core still carried the carbon signature of the years when the person was growing, roughly the first 17 years of life, while muscle samples showed continuous turnover. In plain terms, the core of your Achilles tendon is laid down during childhood and adolescence and is essentially not replaced afterward. The authors suggested this likely explains why tendon regenerates so poorly.

The three phases of healing

After a tear, tendon repair moves through three overlapping phases, as summarized in a 2019 review of tendon healing biology:

1. Inflammatory phase, lasting days. A clot forms, and immune cells move in to clear damaged tissue and release chemical signals that call in repair cells.
2. Proliferative phase, lasting weeks. Fibroblasts, the cells that make connective tissue, multiply and lay down a provisional matrix made mainly of type III collagen. This early tissue is disorganized and weak.
3. Remodeling phase, lasting months to years. The provisional matrix is gradually reorganized and type I collagen increases, but the fibers rarely return to their original tight alignment.

Why healed tissue is not the same as original tissue

Adult tendon heals by scarring, not by true regeneration. The same review states that injured tendons never regain the mechanical strength of the uninjured tendon, which is one reason re-injury is common. Scar can also stick to surrounding structures. After surgical repair of the flexor tendons in the hand, 30 to 40 percent of patients still develop adhesions that limit function. Ligaments, which are built from similar collagen, also heal with scar tissue.

A tear and a tendinopathy are different problems

Most people searching for help with a tendon do not have a fresh rupture. They have tendinopathy: a painful, gradually developing overuse condition such as Achilles or patellar tendon pain, tennis elbow, or rotator cuff pain. Tendinopathy involves degenerative change in the tendon that builds up over time. This distinction matters a great deal, because nearly every BPC-157 tendon experiment studied a fresh surgical cut in a healthy young animal, not a worn, chronically painful tendon.

What BPC-157 is and how it is proposed to work

BPC-157 is a synthetic chain of 15 amino acids. It is described as a fragment of a larger protein, body protection compound, reported in human gastric juice, and it was first synthesized by researchers at the University of Zagreb in Croatia in the early 1990s. It has also been studied under the names PL 14736 and Bepecin, originally as a possible treatment for ulcerative colitis. For a full overview of its origin, safety questions, and legal status, see the companion guide on what BPC-157 is.

Proposed mechanisms from cell studies

The mechanism work in tendon comes mainly from laboratory dishes, not from living people. Three findings are cited most often:

• Cell migration and survival. In a 2011 study using fibroblasts taken from rat Achilles tendon, BPC-157 did not directly make the cells multiply. It did speed the outgrowth of cells from tendon pieces, increased cell survival under hydrogen peroxide stress, and increased cell migration in a dose-dependent way, apparently through a signaling route called the FAK-paxillin pathway.
• Growth hormone receptor. A 2014 study from the same Taiwanese group found that BPC-157 raised growth hormone receptor levels in cultured rat tendon fibroblasts, so that added growth hormone then stimulated more cell growth. This was a cell culture finding. It has not been shown in human tendon.
• Blood vessel growth. A 2009 study reported no direct blood-vessel-forming effect of BPC-157 on cell cultures, but found increased VEGF (a signal that drives new blood vessel growth) in healing muscle and tendon of treated animals.

These are plausible leads, but they remain leads. In its 2026 review of BPC-157, the FDA noted that the molecular targets of BPC-157 have not been identified, that dose-response relationships have not been established, and that its mechanisms of action remain poorly understood, which makes it hard to judge how biologically plausible the claimed effects are.

The rat studies, one by one

The animal work is the heart of the case for BPC-157, so it deserves a careful look. Most of it comes from one research group at the University of Zagreb, and the designs follow a common template: a surgical injury in rats, BPC-157 given once daily starting about 30 minutes after surgery (usually at 10 micrograms or 10 nanograms per kilogram of body weight, injected into the abdominal cavity), and comparison with saline-treated controls. According to the 2025 systematic review, the Zagreb tendon, ligament, and muscle studies all used male Wistar rats.

Achilles tendon transection, 2003

In the study that started the tendon interest, published in the Journal of Orthopaedic Research, the right Achilles tendon of rats was cut through 5 millimeters above the heel bone, leaving a large gap between the cut ends. The tendon was not stitched. Rats received BPC-157 at one of three doses or saline once daily, and were assessed at days 1, 4, 7, 10, and 14.

Treated rats did better on every type of measure reported. Biomechanically, the healing tendon tolerated a higher load before failing. Functionally, scores on the Achilles functional index (a measure based on the animal's paw prints when walking) were significantly higher. Under the microscope there were more fibroblasts and more collagen formation, and the visible defect was smaller. Control animals, by contrast, showed what the authors called severely compromised healing.

Achilles tendon detached from bone, 2006 and 2008

A 2006 study cut the rat Achilles tendon sharply away from the heel bone, a model of tendon-to-bone healing, and followed animals for up to 21 days. BPC-157 improved the functional index, load to failure, stiffness, and collagen organization, with more type I collagen. The same study gave some rats a corticosteroid, 6-alpha-methylprednisolone, which consistently worsened healing, and BPC-157 reduced that worsening.

A 2008 follow-up in 72 male Wistar rats looked only at the first four days after the same injury. BPC-157 improved early function, reduced a marker of inflammatory cell activity called myeloperoxidase, and increased new blood vessel formation. The corticosteroid also reduced inflammation but decreased new vessel formation and did not improve early function.

Medial collateral ligament transection, 2010

The main ligament study cut the medial collateral ligament (MCL), the ligament on the inner side of the knee, in rats and followed them for 90 days. BPC-157 was given three ways: by abdominal injection, in drinking water, or as a thin layer of cream at the injury site. The authors reported consistent functional, biomechanical, macroscopic, and microscopic improvement with all three routes. The systematic review summarized the result as less knee instability and contracture and better ligament strength measures.

This was the only ligament study the 2025 systematic review identified. It listed no BPC-157 study of the anterior cruciate ligament (ACL), the knee ligament that most often leads people to look for healing aids.

Muscle injuries, 2006 to 2010

Three rat studies tested muscle. In 2006, the quadriceps muscle was cut completely across, an injury that does not heal on its own in the rat, and treated animals showed better load to failure, walking recovery, and muscle fiber regeneration over 72 days. In 2008, a standardized crush injury to the calf muscle healed faster with BPC-157 given by injection or as a cream over 14 days. In 2010, the same crush injury was combined with a systemic corticosteroid, which markedly worsened healing, and BPC-157 was reported to reverse that impairment.

Muscle-tendon junction and muscle-to-bone detachment, 2021 and 2025

More recent Zagreb studies moved to harsher injuries. In 2021, the quadriceps tendon was dissected away from its muscle, a defect that does not heal spontaneously in rats, and BPC-157 given by injection or in drinking water for up to 42 days was reported to close the defect and counteract muscle wasting. In 2025, oral BPC-157 was reported to bring about reattachment of a quadriceps muscle detached from bone, while untreated animals were left with a permanently bent knee.

An independent test in 2026

One of the most informative studies is also one of the newest, because it comes from an unrelated research group. In July 2026, Turkish researchers published a trial in 32 male Sprague-Dawley rats whose Achilles tendons were cut and surgically repaired. The rats were randomly assigned to four groups of eight: control, BPC-157 at 10 micrograms per kilogram per day, TB-500, or both peptides, all given for four weeks.

The results were more modest than the earlier literature. Maximum load to failure was higher in both peptide groups than in controls, but the difference reached statistical significance only for TB-500. On tissue scoring, the BPC-157 group had numerically better scores that did not reach statistical significance for total scores. The combination added nothing beyond either peptide alone. The authors called the study exploratory and the findings preliminary. For more on the pairing, see the guide on combining BPC-157 and TB-500.

Why promising animal results often fail in people

Consistent results in rats are a reason to run human trials. They are not a substitute for them. The history of medicine gives good reason for caution, and several features of the BPC-157 literature add to it.

The general track record

An analysis of highly cited animal studies, summarized in a 2010 PLoS Medicine review, found that only about one third translated at the level of human randomized trials, and about one tenth of the interventions were later approved for use in patients. Stroke research is the cautionary example: about 500 treatment strategies were reported to improve outcomes in animal models, yet only two proved effective in patients.

The same review identified recurring reasons. Few animal studies reported random allocation, and fewer still reported blinded assessment of outcomes. Sample size calculations were reported in 0 to 3 percent of studies. Publication bias, the tendency for positive results to be published and negative ones to stay in a drawer, was estimated to account for around one third of the benefit reported in systematic reviews of animal stroke studies. Animals were typically young and healthy, and treatment began a median of 10 minutes after the injury, which is not achievable in a clinic.

How those problems apply to BPC-157

• One group, one template. The large majority of tendon, ligament, and muscle studies come from a single laboratory network in Zagreb using very similar designs. Independent replication is what turns an interesting finding into a reliable one, and an independent tendon study in 2026 found smaller and statistically uncertain effects for BPC-157.
• Every published study is positive. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine noted that all the published studies report beneficial effects, and said this suggests possible publication bias and raises questions about how robust and reproducible the benefits are.
• The injury is not your injury. A clean surgical cut in a healthy young male rat is a different biological problem from a degenerated tendon in a 45-year-old runner, or a rotator cuff that has frayed over a decade.
• Treatment started within 30 minutes. In nearly every study the first dose was given half an hour after the injury. People usually seek treatment days, weeks, or months later, often for chronic pain, which the rat studies did not model.
• No dose-response has been established. The Zagreb studies often report similar benefits at 10 micrograms and at 10 nanograms per kilogram, a thousandfold difference. Most real drug effects grow with dose over some range. The FDA specifically noted the absence of established dose-response relationships.
• Short-lived in the body. Pharmacokinetic studies in rats and dogs, summarized in the 2025 systematic review, report a half-life of less than 30 minutes. How a once-daily dose that clears so quickly would drive weeks of tissue remodeling has not been explained.
• Short follow-up for safety. The systematic review found that no study assessed adverse events beyond 6 weeks after single or repeated dosing in animal models.

The state of human evidence

This is the shortest section of the article because there is so little to report. As of September 2026, no randomized controlled trial of BPC-157 for any tendon, ligament, or muscle injury has been published.

The one musculoskeletal study

The 2025 systematic review in HSS Journal screened 544 articles and included 36 studies: 35 preclinical and 1 clinical. That one clinical study, published in 2021, was a retrospective chart review from a single private clinic in Florida. Seventeen patients had received a BPC-157 injection into the knee joint, alone or combined with thymosin beta-4, for knee pain of various and mostly unspecified causes. Sixteen were reached by phone, most of them 6 months to 1 year after the injection, and were asked to recall their pain before and after.

Of the 12 who received BPC-157 alone, the authors reported that 11 had significant improvement, and 7 of the 12 said relief lasted more than 6 months. There was no control group, no blinding, no imaging, and no standardized measure of function. The authors themselves noted that no specific tools were used to measure function, quality of life, or stiffness.

That design cannot separate a drug effect from placebo response, natural recovery, or the simple effect of injecting fluid into a joint. Improvement after a placebo injection can be large. In the saline-controlled Achilles trial discussed below, the saline group improved by more than 20 points on a 100-point scale. It is also worth noticing that this study was about knee joint pain, not a diagnosed tendon or ligament tear.

Other human exposure

For its July 2026 advisory committee meeting, the FDA searched the medical literature and found five clinical studies in which BPC-157 had been given to people by any route:

• A placebo-controlled phase 1 study of rectal enemas in healthy volunteers (32 randomized, 24 received BPC-157), reported only as meeting abstracts in 2002 and 2003.
• A randomized, placebo-controlled study of enemas in 53 people with mild to moderate ulcerative colitis, reported only as a 2005 meeting abstract.
• The knee injection chart review described above, with doses of 2 to 4 milligrams given once or twice.
• A single-arm study of bladder wall injections in 12 women with interstitial cystitis.
• A 2025 pilot in which 2 adults received intravenous infusions on two consecutive days.

No serious adverse events were reported in these studies. The FDA's assessment, though, was that they were short, small, used exploratory doses, and provided limited safety information, and that safety monitoring in most of them was unclear. The agency also found a phase 1 oral tablet study registered in 2015 by a company called PharmaCotherapia and run at a hospital in Tijuana, Mexico, with an estimated enrollment of 42 healthy volunteers. Its status on ClinicalTrials.gov is listed as unknown, no results have been posted, and the FDA could not find an associated publication.

Notably, BPC-157 had been nominated to the FDA for use in tendonitis, among other conditions. The agency did not evaluate that use, because the nomination did not include enough information and the FDA could not identify any clinical studies of BPC-157 in that population.

Trials now registered

The encouraging news is that a proper trial is finally being set up. A registry listing is not evidence, and entries are self-reported by sponsors. ClinicalTrials.gov also carries a 2026 record for a phase 2 BPC-157 hamstring strain trial in China (NCT07437547), but a second record from the same sponsor, with the same contacts, describes itself as a "fictional study" and an example record, so this article does not count either one as a real trial. As of September 2026, one musculoskeletal listing appears genuine:

Rotator cuff repair (NCT07803250). The University of Arkansas registered a randomized, double-blind, saline-controlled phase 1 pilot in September 2026. Participants would self-inject BPC-157 or saline under the skin once daily for 90 days after arthroscopic rotator cuff repair, with healing assessed by MRI, strength testing, and patient-reported outcomes. It is listed as not yet recruiting, with an estimated start in January 2027. Its enrollment field says 30, while its summary says 20. The registration itself states that BPC-157 has not undergone formal human clinical trials.

The trial has no results. Until trials like this one report, any statement about how well BPC-157 works for a human tendon or ligament, at what dose, for how long, or how safely, is a guess.

Safety unknowns and regulatory status

FDA status as of September 2026

As of September 2026, BPC-157 is not FDA approved for any condition, and it is not a component of any FDA-approved drug. Its status for pharmacy compounding has shifted several times and is still unsettled:

• On September 29, 2023, the FDA placed BPC-157 in Category 2 of its interim list of bulk drug substances, the category for substances that may present significant safety risks in compounding.
• On April 22, 2026, after a seven-day notice posted on April 15, the FDA removed BPC-157 and other peptides from Category 2 because the parties that had nominated them withdrew their nominations. According to a legal analysis of the change, removal from Category 2 did not automatically make BPC-157 eligible for compounding.
• The FDA's web page on bulk substances that may present significant safety risks, updated in April 2026, still lists BPC-157, now under the heading of substances that were nominated but withdrawn. It states that compounded BPC-157 may pose a risk of immune reactions for certain routes of administration, may involve peptide-related impurities, and that the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.
• On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee was asked whether BPC-157 free base and BPC-157 acetate should be placed on the list of substances that pharmacies may compound. The FDA had not posted minutes as of September 2026, but ABC News and a McDermott Will and Schulte legal summary both report a vote of 8 to 6, with 1 abstention, in favor. FDA staff scientists had recommended against this, citing a substance that is not well characterized, a lack of safety and immunogenicity information, and insufficient evidence of effectiveness.
• The committee's vote is advisory and not binding. Formally adding a substance to the list requires notice-and-comment rulemaking, which the McDermott analysis says could happen in 2027 or stretch over several years.

Whatever the final compounding decision, it will not be a finding that BPC-157 works. Committee members who voted no said they worried that listing the peptide would create a false impression that it had been evaluated to the same standard as an approved drug. Your prescriber can tell you what the rules are at the time you are reading this, since they may have changed.

Safety signals and gaps

The honest summary of human safety is that it is unknown. The systematic review found no clinical safety data at all. The FDA's 2026 review adds a few specific points worth knowing:

• Animal toxicology. In 28-day studies in rats and dogs given intramuscular BPC-157, the FDA described clinically relevant signals, including changes in a blood clotting test (the aPTT) and liver-related changes such as increased ALT, glucose, and triglycerides. Longer studies were not available to confirm or extend these findings.
• Cancer risk has not been tested. No carcinogenicity studies exist. Because BPC-157 appears to promote blood vessel growth in healing tissue, and abnormal blood vessel growth is involved in tumor growth, this is a theoretical concern that has been raised. Some laboratory work suggests BPC-157 may counteract tumor-related signaling instead. Neither possibility has been tested in people.
• Immune reactions. The FDA considers injected peptides of this size a potential immunogenicity risk, meaning the body may form an immune response to the peptide or to impurities and clumped peptide in the product. That risk is higher with injection than with oral use.
• Adverse event reports. The FDA described a report in which a person using a research-only product containing BPC-157 and TB-500 developed widespread skin darkening and darkening of the gums, which returned when the product was restarted. Because two peptides were involved, the cause could not be assigned to either one.
• Pregnancy. One animal study did not find birth defects in rats, but a complete set of reproductive studies has not been done.

Product quality

No BPC-157 product, from any source, has had its identity, purity, sterility, or dose reviewed by the FDA. In its review of products in the market generally, the FDA found that certificates of analysis for BPC-157 typically report purity alone, without limits or testing for specific impurities, and the systematic review authors warned that adverse effects are possible from unregulated manufacturing and contamination. With an injectable product, sterility is a separate and serious concern. Those warnings apply with the most force to vials sold online for research use only, a label used to sidestep drug law rather than a description of who buys them: nobody has verified what is in the vial, nobody has screened the buyer, and self-injecting places all of those risks on you. A physician-provided route cannot substitute for FDA review, but it can add what an anonymous seller cannot: an independent laboratory test of each batch for identity and purity, a certificate of analysis the patient can see, reconstitution in the office, written dosing instructions, and medical follow-up.

Rx2BFIT does not use a compounding pharmacy. Its BPC-157 comes from a supplier whose batches are tested by an independent laboratory for identity and purity, with a certificate of analysis on file, and is reconstituted in the office under Dr. Patel's supervision. It is not an FDA-approved medication, and that, along with the known risks and the limits of the evidence, is reviewed with every patient before starting.

If you compete in sport

BPC-157 is named on the World Anti-Doping Agency's 2026 Prohibited List under category S0, non-approved substances, and is prohibited at all times, in and out of competition. It has been banned since 2022. The US Anti-Doping Agency says a therapeutic use exemption is unlikely to be granted because permitted alternatives exist, and anti-doping laboratories have published urine methods that pick up BPC-157 breakdown products at very low concentrations. If you are subject to drug testing, a prescription does not protect you.

When to seek urgent care

Regardless of what treatment you are considering, get urgent medical attention for a sudden pop or snap followed by weakness or inability to bear weight, since that pattern can mean a complete rupture and needs prompt assessment. After any injection, seek care promptly for spreading redness, warmth, swelling, pus, or fever, which can signal infection, and treat hives, facial or throat swelling, or trouble breathing as an emergency.

What is proven for tendon and ligament recovery

The contrast with BPC-157 is sharp. Several treatments for tendon and ligament problems have been tested in randomized trials in people, and the results are instructive both for what works and for what turned out not to.

Progressive loading: the foundation

Tendon adapts to load. Carefully dosed, progressively heavier strengthening is the best-supported treatment for tendinopathy, and exercise-based loading has long been the dominant non-surgical strategy for Achilles and patellar tendon pain. The modern approach dates to a 1998 Swedish study of 15 recreational athletes with chronic Achilles tendinosis who had failed conventional treatment. After 12 weeks of heavy-load eccentric calf training (slow heel lowering under load), all 15 were back to their previous running level, while 15 comparison patients treated conventionally all ultimately went on to surgery. That study was small and not randomized, but it launched two decades of trials.

A 2015 randomized trial of 58 people with chronic midportion Achilles tendinopathy compared eccentric training with heavy slow resistance training for 12 weeks. Both groups improved significantly in pain and function, the gains were maintained at 52 weeks, and tendon thickness and abnormal vessel growth decreased. Neither program was superior. Adherence was higher with heavy slow resistance (92 percent versus 78 percent of sessions). A 2013 systematic review of 32 studies reached a similar conclusion: there is little evidence that the eccentric component must be isolated, and the consistent predictor of getting better was improved muscle performance.

Two honest caveats apply. Loading is slow, with programs measured in months. And it does not work for everyone: the same review noted that in some studies up to 45 percent of patients may not respond to isolated eccentric training. That frustrating gap is precisely why people go looking for injections and peptides.

Platelet-rich plasma

Platelet-rich plasma (PRP) is a concentrate of your own platelets, injected to deliver growth factors to the tendon. It is a useful comparison for BPC-157, because it also began with appealing biology and encouraging animal and observational data. Then it was tested properly.

• A 2010 double-blind trial in JAMA randomized 54 people with chronic Achilles tendinopathy to PRP or saline injection, with all participants doing eccentric exercises. At 24 weeks the PRP group had improved by 21.7 points on the 100-point VISA-A scale and the saline group by 20.5 points, with no significant difference.
• A 2021 JAMA trial at 24 sites randomized 240 people to a single PRP injection into the tendon or a sham procedure. At 6 months, VISA-A scores were 54.4 with PRP and 53.4 with sham. The authors concluded that the findings do not support PRP for chronic midportion Achilles tendinopathy.
• A 2021 Cochrane review of lateral elbow pain (tennis elbow) pooled 32 studies with 2,337 participants. With moderate certainty, autologous blood or PRP injection provided little or no clinically important benefit over placebo injection at 3 months: pain was 0.16 points better on a 10-point scale.

The lesson is not that biologic injections can never work. It is that a good mechanism story, positive animal studies, and enthusiastic patient reports were all present for PRP, and the sham-controlled trials still came back flat for these conditions. BPC-157 currently has less human evidence than PRP had before those trials were run.

Shockwave therapy

Extracorporeal shockwave therapy delivers pressure pulses to the tendon through the skin. A 2018 systematic review in the British Journal of Sports Medicine found low-level evidence that it is comparable to eccentric training and better than a wait-and-see approach at 4 months for midportion Achilles tendinopathy, and moderate-level evidence that focused shockwave was no better than placebo for patellar tendinopathy. Thirteen of the included studies had a high risk of bias. It is a reasonable second-line option for some tendons, with modest and uneven support.

Corticosteroid injections

A 2010 systematic review in The Lancet pooled 41 randomized trials with 2,672 participants. Corticosteroid injections reduced tendon pain in the short term, but the effect reversed later. For tennis elbow, the injection had a large benefit over no intervention at about 4 weeks, yet no intervention was favored at 26 weeks and at 52 weeks. Serious adverse events were rare in the trials: 1 tendon rupture among 991 participants who received corticosteroid injections. Short-term relief with a worse long-term course is a trade worth discussing in detail with your doctor.

Ruptures and ligament tears: structured rehabilitation and surgery

For complete Achilles ruptures, a 2019 BMJ meta-analysis of 29 studies found re-rupture in 2.3 percent of people after surgery versus 3.9 percent without surgery, while complications were more common with surgery (4.9 percent versus 1.6 percent), mainly infection. In studies that used accelerated functional rehabilitation with early movement, the re-rupture difference was no longer significant.

For the ACL, a 2010 New England Journal of Medicine trial randomized 121 young, active adults with an acute tear to structured rehabilitation plus early reconstruction or to rehabilitation with the option of later surgery. At 2 years, knee scores had improved by 39.2 and 39.4 points respectively, with no significant difference, and 36 of the 59 people in the optional-surgery group had not needed reconstruction. In both injuries, the common factor in good outcomes is well-structured rehabilitation.

Myths versus realities

Myth: BPC-157 is proven to heal tendons

Reality: it is reported to improve healing of surgically cut tendons in rats. In people, it has never been tested against a placebo for any tendon or ligament condition. The 2025 systematic review graded the entire body of evidence as level IV and level V, the lowest tiers.

Myth: it comes from the stomach, so it must be safe

Reality: the product sold is a synthetic peptide, often injected, at doses and by routes the body never encounters naturally. Origin does not establish safety. The FDA's position is that it lacks sufficient information to know whether BPC-157 would cause harm in humans, and long-term, cancer-related, and complete reproductive safety studies do not exist.

Myth: if a pharmacy can compound it, it has been vetted

Reality: compounded drugs are not FDA approved, and inclusion on a compounding list is not a judgment that a substance is effective. FDA staff recommended against listing BPC-157, and the advisory committee that disagreed did so by a reported two-vote margin.

Myth: the dose is well worked out

Reality: no human dose-finding study for musculoskeletal injury has been published, so the doses circulating online do not rest on human trial data. Any decision about dosing belongs with a licensed prescriber who can explain what the number is based on.

Myth: peptides let you skip rehab

Reality: the registered rotator cuff trial gives BPC-157 on top of the standard rehabilitation protocol, not in place of it. Nothing in the evidence suggests any injection replaces progressive loading.

Questions to ask your doctor

If you are weighing BPC-157 for a tendon or ligament problem, these questions can help you and your prescriber have a clear-eyed conversation. General background on this category of treatment is available on the performance and recovery and BPC-157 treatment pages.

• What exactly is my diagnosis: a tendinopathy, a partial tear, a complete tear, or a joint problem? Has it been confirmed by examination or imaging?
• Have I completed a properly progressed loading program for long enough, usually at least 12 weeks, and if it has stalled, why?
• What human evidence supports BPC-157 for my specific condition, and how does that compare with the evidence for my other options?
• Where does the product come from, is each batch tested by an independent laboratory for identity and purity, can I see the certificate of analysis for my batch, and who reconstitutes it?
• What is the dose based on, how long would I use it, and what would make us stop?
• Do I have any history, such as a current or past cancer, a clotting disorder, liver disease, or pregnancy, that raises extra concern given the untested areas?
• Am I subject to drug testing at work or in sport?
• Is there a clinical trial I could join instead, so that my experience adds to the evidence?

A thoughtful prescriber will welcome these questions. If BPC-157 is being presented to you as proven, risk free, or a replacement for rehabilitation, that is not what the evidence says. Related reading includes the guide to TB-500 and thymosin beta-4, the peptide most often paired with BPC-157 in recovery products.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.